title: A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
abstract: The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders.
authors.affiliation: St Michael's Hospital, Department of Medicine and University of Toronto, Toronto, ON, Canada. teitelj@smh.ca
authors.forename: J
authors.initials: J
authors.lastname: Teitel
authors.forename: E
authors.initials: E
authors.lastname: Berntorp
authors.forename: G
authors.initials: G
authors.lastname: Dolan
authors.forename: K
authors.initials: K
authors.lastname: Fischer
authors.forename: A
authors.initials: A
authors.lastname: Gringeri
authors.forename: C
authors.initials: C
authors.lastname: Kessler
authors.forename: T
authors.initials: T
authors.lastname: Lambert
authors.forename: C
authors.initials: C
authors.lastname: Leissinger
authors.forename: L
authors.initials: L
authors.lastname: Nemes
authors.forename: M
authors.initials: M
authors.lastname: Shima
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors